PLoS One, 13(4):e0196033, Apr 2018
PMDID: 29694419
"Quality of life patient-reported outcomes for locally advanced cutaneous melanoma",
Melanoma Research, 28(2):134-142, Apr 2018
PMDID: 29261570
Journal of Surgical Oncology, 117(4):579-587, Mar 2018
PMDID: 29529343
Journal of Surgical Oncology, 115(7):891-897, Jun 2017
PMDID: 28230241
Cell Death and Disease 8(2):e2584; Feb 2017
PMDID: 28151483
"Intralesional PV-10 for in-transit melanoma - A single-center experience.",
Journal of Surgical Oncology, 114(3):380-4, Sep 2016
PMDID: 27237868
Oncotarget, 7(25):37893-37905, June 2016
PMDID: 27177220
"The Potential of Intralesional Rose Bengal to Stimulate T-Cell Mediated Anti-Tumor Responses",
Journal of Clinical & Cellular Immunology, (2015) 6(4):343, Jul 2015
PMDID: 26618054
"Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma",
Annals of Surgical Oncology, (7):2135-42, Oct 2014
PMDID: 25348780
Xenobiotica, 44(7):606-14, Jul 2014
PMDID: 24405273
"Intralesional therapy with PV-10 (Rose Bengal) for in-transit melanoma",
Journal of Surgical Oncology, 109(4):314-9, Mar 2014
PMDID: 24510477
PLoS ONE, 8(7):e68561, Jul 2013
PMDID: 23874673
"Novel use of Rose Bengal (PV-10) in two cases of refractory scalp sarcoma",
ANZ Journal of Surgery, 83:1-2:93, Jan 2013
PMDID: 23350981
Melanoma Research, 20:48, Jan 2010
PMDID: 20009957
"Interference from rose bengal with total bilirubin measurement.",
Clinical Chemistry, 55(5):1040-1, May 2009
PMDID: 19264853
"Chemoablation of metastatic melanoma using intralesional Rose Bengal",
Melanoma Research, 18:405, Dec 2008
PMDID: 18830132
"Systemic Phototoxicity following Intralesional Rose Bengal for Subcutaneous Melanoma Metastases",
Dermatology, 2008;216:361-362, Feb 2008
PMDID: 18292654
"Topical Rose Bengal: Pre-Clinical Evaluation of Pharmacokinetics and Safety",
Lasers in Surgery and Medicine, 32(2):101-10, Nov 2003
PMDID: 12561042
"Imaging Photosensitizer Distribution and Pharmacology using Multiphoton Microscopy",
In "Functional Imaging and Optical Manipulation of Living Cells and Tissues".
SPIE, Paper 4622A-14, Jan 2002
SDLID: 872032
"Functional Imaging of Photosensitizers using Multiphoton Microscopy",
In "Multiphoton Microscopy in the Biomedical Sciences II".
SPIE, Paper 4620-29, Jan 2002
SDLID: 871867
"Treatment of murine cutaneous melanoma with near infrared light",
Photochemistry and Photobiology, 75(3):296-301, Mar 2002
PMDID: 11950096
"What is the OPTiMal Way to Manage In-Transit Disease?",
Annals of Surgical Oncology, 23(13):4126-4129, Dec 2016
PMDID: 27380046
"Malignant melanoma - The cradle of anti-neoplastic immunotherapy",
Critical Reviews in Oncology/Hematology, 2016;106:25-54, Oct 2016
PMDID: 27637351
Pharmacy and Therapeutics, 2016;41(9):581-586, Sep 2016
PMDID: 27630529
Journal of Photochemistry and Photobiology B, 2016;162:258-265, Sep 2016
PMDID: 27394008
"The Role of Intralesional Therapies in Melanoma.",
Oncology, 30(5):436-41, May 2016
PMDID: 27188674
"Intralesional immunotherapy as a strategy to treat melanoma.",
Expert Opinion on Biological Therapy, 16(5):619-26, May 2016
PMDID: 26898656
"Intralesional therapy for advanced melanoma: promise and limitation",
Current Opinion in Oncology, 27(2):151-6, Mar 2015
PMDID: 25629369
"GNA11 Mutation in a Patient With Cutaneous Origin Melanoma: A Case Report",
Medicine, 2016;95(4):e2124-e2634, Jan 2016
PMDID: 26825879
"Evaluation of small molecule SecA inhibitors against methicillin-resistant Staphylococcus aureus",
Bioorganic & Medicinal Chemistry, 2015;23(21):7061-7068, Nov 2015
PMDID: 26432604
"The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options",
Cancers, 2015;7(3):1154-1177, Jul 2015
PMDID: 26140669
"Treatment of Metastatic Melanoma in an Immunodeficient Patient",
American Medical Student Research Journal, 2015;2(1):138-142, May 2015
AMSRJ: 2015:2(1)
"Intralesional therapy for in-transit and satellite metastases in melanoma.",
Surgical Oncology Clinics, 2015;24(2):299-308, Apr 2015
PMDID: 25769713
"Photo-induced inhibition of Alzheimer's β-amyloid aggregation in vitro by rose bengal",
Biomaterials, 2015;38:43-49, Jan 2015
PMDID: 25457982
"Intralesional therapy for metastatic melanoma",
Expert Opinion on Pharmacotherapy, 2014;15(18):2629-39, Dec 2014
PMDID: 25381015
Journal of Immunotoxicology, 2014;11(4):367-75, Oct 2014
PMDID: 24575814
"Selective toxicity of rose bengal to ovarian cancer cells in vitro",
Int J Physiol Pathophysiol Pharmacol, 2012;4(2):99-107, Jun 2012
PMDID: 22837809
"Local and Intralesional Therapy of In-Transit Melanoma Mestasases",
Journal of Surgical Oncology, 2011;104:391-396, Sep 2011
PMDID: 21858834
"Current and Planned Multicenter Trials for Patients WIth Primary or Metastatic Melanoma",
Journal of Surgical Oncology, 2011;104:430-437, Sep 2011
PMDID: 21858839
"Intralesional agents in the management of cutaneous malignancy: a review.",
Journal of the American Academy of Dermatology, 64(2):413-22, Feb 2011
PMDID: 20334952
Pharmacy & Therapeutics, 35(8):469-474, Aug 2010
PMDID: 20844697
"131I-rose bengal therapy in hepatoblastoma patients.",
European Journal of Cancer, 27(5):613-5, May 1991
PMDID: 1647184
W. Alexander, Jun 2013
"Immune Modulation by Topical PH-10 Aqueous Hydrogel (Rose Bengal Disodium) in Psoriasis Lesions",
8th International Psoriasis from Gene to Clinic Congress, Abstract 115, Poster P013, November 2017
"Preliminary Results of a Phase 1b/2 Study of PV-10 and Pembroluzimab in Stage IV Melanoma",
Society for Melanoma Research 2017 Congress, Presentation P15-1, October 2017
"Intralesional Rose Bengal as an Oncolytic Immunotherapy for Hepatic Tumors",
26th Conference of the Asian Pacific Association for the Study of the Liver (APASL), Shanghai, China, Presentation #PP0530, February 2017
"Percutaneous Rose Bengal as an Oncolytic Immunotherapy for Hepatic Metastases",
CIO (Clinical Interventional Oncology) 2017, Hollywood, FL USA, Abstract #15831, February 2017
"Intralesional Rose Bengal in Melanoma Elicits Tumor Immunity via High Mobility Group Box 1",
Society for Immunotherapy of Cancer 30th Annual Meeting
Journal for Immunotherapy of Cancer 2015, 3(Suppl 2):P408, November 2015
6th Asia-Pacific Primary Liver Cancer Expert Meeting, Abstract #P1-84, July 2015
ESMO 17th World Congress on Gastrointestinal Cancer, Abstract #P-116, July 2015
HemOnc Today Melanoma and Cutaneous Malignancies Annual Meeting, Apr 2015
Society for Immunotherapy of Cancer 29th Annual Meeting
Journal for Immunotherapy of Cancer 2014, 2(Suppl 3):P120 doi:10.1186/2051-1426-2-S3-P120, Nov 2014
European Society For Medical Oncology, Abstract #1120P, Sep 2014
American Society of Clinical Oncology, Jun 2014
European Cancer Congress 2013, Abstract No. 3.755, Sep 2013
"Rose Bengal - Phototoxicity versus Intrinsic Cytotoxicity"
8th World Congress of Melanoma, Free Communications 4: Melanoma Treatment, Abstract FC-021, Jul 2013
American Association for Cancer Research Annual Meeting, Abstract #1248, Apr 2013
American Association for Cancer Research Annual Meeting, Abstract #4755, Apr 2013
"Generation of an Antitumor Response and Immunity Using a Small Molecule Drug (PV-10)",
Society for Immunotherapy of Cancer 27th Annual Meeting [ poster ]
Journal of Immunotherapy Vol. 35, No. 9, Nov 2012
"Immuno-chemoablation of metastatic melanoma with intralesional rose bengal",
European Society for Medical Oncology 2012 Congress, Oct 2012
Society of Surgical Oncology Annual Meeting, Mar 2012
"Chemoablation of Metastatic Melanoma with Rose Bengal (PV-10)"
American Society of Clinical Oncology, Jun 2010
"Chemoablation of Melanoma with Intralesional Rose Bengal (PV-10)"
American Society of Clinical Oncology, Jun 2009
Melanoma Research 16(Suppl 1):S8, Sep 2006
"Rose Bengal for melanoma treatment: will it translate to the clinic?",
Melanoma Management, (2015) 2(2):101-103, May 2015
"PV-10 in Advanced Melanoma: High Response Rates, Evidence of Systemic Response",
Cancer Watch, Vol. 22:155-156, Oct 2013
"Rose Bengal-Based Drug Kills Both Primary and Secondary Melanoma Tumors",
Bio Research International, Vol.18 No.5, Sep 2013
"Back to Phase 1: Understanding Systemic Effects of PV-10",
Cancer Watch, Vol. 22:21-23, Feb 2013
"ESMO 2012: PV-10 shows sustained response in melanoma",
ecancer news, Oct 2012
"Immunotherapy Update: Ipilimumab and Intralesional Therapies",
Cancer Watch, Vol. 21:135-136, Sep 2012
"Provectus looks to Phase III with positive melanoma data",
Scrip Intelligence, Jun 2012
"Metastatic Melanoma: A Murine Study Confirming an Immune Response with PV-10",
Cancer Watch, Vol. 21:86-89, Jun 2012
"PV-10, aka Rose Bengal: Intralesional Therapy For Metastatic Melanoma",
The Melanoma Letter, Vol. 30, No. 1:5-7, May 2012
"Rose Bengal - More Than Just a Red Food Dye?",
The North Carolina Osteopathic Medical Association News:25, Mar 2012
BioCentury, March 26, 2012
"Individualized Local Treatment Strategies for In-Transit Melanoma",
ONCOLOGY, Feb 2012
"PV-10: A Melanoma Therapeutic in the Pipeline",
Practical Dermatology, January 2012:41-42, Jan 2012
"New Agents Stir Interest in Intralesional Therapy for Cutaneous Metastatic Melanoma",
Cancer Watch, Vol. 20, No. 9:139-140, Sep 2011
"One-year Findings in Metastatic Melanoma Confirm Rose Bengal Benefit",
The Oncology Pharmacist, Vol. 4, No. 1:139-140, Feb 2011
St. Luke's Cancer Connection Letter, Jan 2011
"Melanoma: Rose bengal scores, ipilimumab sees delay",
Oncology News International, Vol. 19, No. 12:139-140, Dec 2010
"Compassionate Input to Phase III",
Trials In Focus, December 6, 2010
"Chemoablation of Metastatic Melanoma",
Cancer Watch, Vol 19, No. 11:164-164, Nov 2010
"Chemoablation of Metastatic Melanoma with PV-10",
Presentation at 4th Interdisciplinary Melanoma & Skin Cancer Centres Meeting, Sydney, AU, Nov 2010
"Skin cancer tumors busted with red dye 'tattoo' trial",
The Courier-Mail, Nov. 4, 2010
"High Responses in Melanoma for Wool Dye/Ocular Stain Rose Bengal",
The Oncology Pharmacist, Vol. 3 No. 7, Oct 2010
"Rose Bengal: From a Wool Dye to a Cancer Therapy",
Pharmacy and Therapeutics, Vol. 35, No. 8:469-469, Aug 2010
"Trial heralding a new day for melanoma meets with guarded enthusiasm",
Oncology News International, Vol. 19, No. 7, Jul 2010
"Robust Response in Metastatic Melanoma to Rose Bengal (PV-10)",
Cancer Watch, Vol. 19, No. 7:109-110, Jul 2010
"Promising Data on Ipilimumab and Other Investigational Melanoma Therapies",
Practical Dermatology, Vol. 7, No. 6:24-25, Jun 2010
"New era in metastatic melanoma",
Molecular Oncology, Vol. 4, N0. 2:91-97, Apr 2010